[
    {
        "Sponsor": "DiaMedica",
        "NCT #": "NCT05065216",
        "Protocol Title": "Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Protocol Number: DM199-2021-001",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "ImmunityBio",
        "NCT #": "NCT03520686",
        "Protocol Title": "A Phase 2, Open-Label, Randomize Stuy of ALT-803, A Fusion Protein Activator of Natural Killer and T Cells, in Combination with Pembrolizumab vs Pmbrolizumab Alone as First-Line Treatment for Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Doterra",
        "NCT #": "NCT05218044",
        "Protocol Title": "Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ",
        "Principal Investigator": "Dennis Holmes, MD"
    },
    {
        "Sponsor": "Pfizer",
        "NCT #": "NCT04821622",
        "Protocol Title": "TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Pfizer",
        "NCT #": "NCT03395197",
        "Protocol Title": "A Phase 3, Randomized, Double\u2011Blind, Placebo\u2011Controlled Study of Talazoparib WITH ENZALUTAMIDE in Metastatic Castration\u2011Resistant Prostate Cancer TALAPRO2",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "ABIOMED ",
        "NCT #": "NCT04763200",
        "Protocol Title": "Impella\u00ae-Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function: The PROTECT IV Trial",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "Caris Life Sciences",
        "NCT #": "NCT05692466",
        "Protocol Title": "DINOSAur: Discovering novel cancer treatment options using a comprehensive NGS-based molecular testing panel in the community setting",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "ABIOMED",
        "NCT #": "\u00a0NCT05334784",
        "Protocol Title": "Use of the Impella ECP\u2122 in Patients Undergoing an Elective or Urgent High-Risk Percutaneous Coronary Intervention",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "AHGL Office of Integrated Research",
        "NCT #": "NCT05703243",
        "Protocol Title": "Discovering novel cancer treatment options using a comprehensive NGS-based liquid molecular testing panel in the community setting. (\u201cDINOSAur II\u201d)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Novartis",
        "NCT #": "NCT05147220",
        "Protocol Title": "A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib",
        "Principal Investigator": "Artin Minaeian, MD"
    },
    {
        "Sponsor": "Janssen",
        "NCT #": "NCT05702034",
        "Protocol Title": "\u201cA Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack LIBREXIA-STROKE\u201d",
        "Principal Investigator": "Lance Lee, MD"
    },
    {
        "Sponsor": "Stemline Therapeutics",
        "NCT #": "NCT05563220",
        "Protocol Title": "Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacastrant in Various Combination In Patients with Metastatic Breast Cancer (ELEVATE)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Philips",
        "NCT #": "NCT04451044",
        "Protocol Title": "Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "PCEC",
        "NCT #": null,
        "Protocol Title": "Prostate   Cancer   Awareness Screening    ",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "MeThinks",
        "NCT #": "NCT06216457",
        "Protocol Title": "Study on the Performance of a Machine Learning Algorithm Recognizing and Triaging Large Vessel Occlusions Using Non-contrast CT Scans (SMART-LVO)",
        "Principal Investigator": "Mikayel Grigoryan, MD"
    },
    {
        "Sponsor": "Teligene",
        "NCT #": "NCT060210342",
        "Protocol Title": "A Phase 2 Study of TL118 for the Treatment of Patients with Solid Tumors Harboring NTRK Gene Fusions",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "TrialLibrary",
        "NCT #": "NCT05514054",
        "Protocol Title": "EMBER 4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer",
        "Principal Investigator": "NA--Registry"
    },
    {
        "Sponsor": "Weill Medical College of Cornell University",
        "NCT #": "NCT06399705",
        "Protocol Title": "REvascularization CHoices Among Under-Represented Groups Evaluation: The\u00a0RECHARGE\u00a0Trial (RECHARGE)",
        "Principal Investigator": "Hambik Tankazyan, DO"
    },
    {
        "Sponsor": "Mercy Health Ohio",
        "NCT #": "NCT05611242",
        "Protocol Title": "Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial (PICASSO)",
        "Principal Investigator": "Mikayel Grigoryan, MD"
    },
    {
        "Sponsor": "Johnson and Johnson",
        "NCT #": "NCT06667076",
        "Protocol Title": "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "AstraZeneca",
        "NCT #": "NCT06380751",
        "Protocol Title": "Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/\u200b6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/\u200b ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01)",
        "Principal Investigator": "Mihran Shirinian, MD"
    },
    {
        "Sponsor": "Medtronic/Orchestra BioMed",
        "NCT #": "NCT06059638",
        "Protocol Title": "BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (BACKBEAT)",
        "Principal Investigator": "John P. McKenzie, MD"
    }
]
